Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?

OBJECTIVE To evaluate the use of radionuclide bone scintigraphy following biochemical recurrence after radical retropubic prostatectomy (RRP) for localized prostate cancer. PATIENTS AND METHODS Of 1197 patients undergoing RRP we identified those with biochemical recurrence and who had also had a bon...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2004-08, Vol.94 (3), p.299-302
Main Authors: Gomez, Pablo, Manoharan, Marugesan, Kim, Sandy S., Soloway, Mark S.
Format: Article
Language:English
Subjects:
Aged
biochemical recurrence
Biological and medical sciences
Bone Neoplasms - blood
Bone Neoplasms - diagnostic imaging
Bone Neoplasms - secondary
bone scan
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
Neoplasm Recurrence, Local
Nephrology. Urinary tract diseases
Osteoarticular system. Muscles
Postoperative Care - methods
Prognosis
prostate carcinoma
Prostate-Specific Antigen - blood
Prostatectomy
Prostatic Neoplasms - blood
Prostatic Neoplasms - surgery
radical prostatectomy
Radionuclide Imaging
Radionuclide investigations
Retrospective Studies
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To evaluate the use of radionuclide bone scintigraphy following biochemical recurrence after radical retropubic prostatectomy (RRP) for localized prostate cancer. PATIENTS AND METHODS Of 1197 patients undergoing RRP we identified those with biochemical recurrence and who had also had a bone scan. Biochemical recurrence was defined as a prostate specific antigen (PSA) level of ≥ 0.4 ng/mL. Patients with indeterminate bone scan findings and those in whom the interval between the PSA test and the bone scan was >3 months were excluded. Patient age, PSA level and other relevant pathological details were recorded. Clinical symptoms at the time of bone scan, androgen deprivation after RRP, bone scintigram details and time to recurrence were documented. RESULTS Of the 1197 patients, 153 (12.8%) had a biochemical recurrence and 35 (23%) of these had a total of 44 bone scans taken over a mean (sd) follow‐up of 70.4 (35.6) months; 34 (77%) bone scans were negative (group 1) and 10 (33%) positive (group 2). In group 1 the mean PSA at the bone scan was 5.2 ng/mL; 76% of the patients had a PSA of 7 ng/mL. The only significant difference between the groups was the PSA at the time of the bone scan (P 
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2004.04927.x